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Introduction: Post-transplantation proteinuria is a risk factor for graft failure. A progressive
decline in renal graft function is a predictor for mortality in kidney transplant patients.
Objectives: To assess the development and the progression of urinary protein excretion (UPE)
in  the ﬁrst year post-transplant in recipients of kidney transplants and its effect on patient
and graft outcomes.
Materials and methods: We  analysed 1815 patients with 24-h UPE measurements available
at  3 and 12 months post-transplant. Patients were divided based on their UPE level: below
300  mg,  300–1000 mg and over 1000 mg (at 3 and 12 months), and changes over time were
analysed.
Results: At 3 months, 65.7% had UPE below 300 mg/24 h, 29.6% 300–1000 mg/24 h and 4.7%
over  1000 mg/24 h. At one year, 71.6% had UPE below 300 mg/24 h, 24.1% 300–1000 mg/24 h
and  4.4% over 1000 mg/24 h.
In  208 patients (12%), the UPE progressed, in 1233 (70.5%) it remained stable and in 306
(17.5%) an improvement was observed.
We  found that the level of UPE inﬂuenced graft survival, particularly if a progression
occurred.
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Recipient’s age and renal function at one year were found to be predictive factors for
mortality, while proteinuria and renal function were predictive factors for graft survival.
Conclusions: Proteinuria after transplantation, essentially when it progresses, is a marker of
a  poor prognosis and a predictor for graft survival. Progression of proteinuria is associated
with poorer renal function and lower graft survival rates.
©  2015 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Progresión  de  la  excreción  urinaria  de  proteínas  después  del  trasplante
renal:  un  marcador  de  mal  pronóstico  a  largo  plazo
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Introducción: La proteinuria después de un trasplante renal constituye un factor de riesgo
para el fallo del injerto. Una disminución progresiva de la función del injerto renal es un
predictor de la mortalidad en los pacientes trasplantados renales.
Objetivos: Analizar la aparición y la progresión de una excreción urinaria de proteínas (EUP)
en  el primer an˜o siguiente al trasplante en pacientes trasplantados renales, y su efecto sobre
la  evolución del paciente y del injerto.
Material y métodos: Analizamos un total de 1815 pacientes en los que se dispuso de deter-
minaciones de la EUP de 24 horas a los 3 y a los 12 meses del trasplante. Dividimos a los
pacientes según el nivel de EUP, de la siguiente forma: inferior a 300 mg,  300-1000 mg y más
de  1000 mg (a los 3 y 12 meses), y analizamos los cambios a lo largo del tiempo.
Resultados: A los 3 meses, el 65,7% presentaban una EUP inferior a 300 mg/24 h, el 29,6% 300-
1000  mg/24 h y el 4,7% más de 1000 mg/24 h. A un an˜o, el 71,6% tenían una EUP inferior a
300  mg/24 h, el 24,1% 300-1000 mg/24 h y el 4,4% más  de 1000 mg/24 h.
En  208 pacientes (12%), la EUP mostró una progresión, en 1233 (70,5%) se mantuvo estable
y  en 306 (17,5%) se observó una mejoría.
Observamos que el nivel de EUP inﬂuía en la supervivencia del injerto, en especial si se
producía una progresión.
La edad y la función renal del receptor al an˜o del trasplante fueron factores predictivos de
la  mortalidad, mientras que la proteinuria y la función renal lo fueron de la supervivencia
del injerto.
Conclusiones: La proteinuria después del trasplante, fundamentalmente cuando muestra una
progresión, es un marcador de mal  pronóstico y un factor predictivo de la supervivencia del
injerto. La progresión de la proteinuria se asocia a una peor función renal y a una tasa de
supervivencia del injerto inferior.
© 2015 Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española de
Nefrología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
In the world of transplants, the introduction of new immuno-
suppressants has led to an improvement in short- and
medium-term graft survival1–3; nevertheless, long-term graft
loss remains a problem.4 The many  factors associated with
these long-term losses have been analysed by a large number
of studies.5 Among them, recent studies6 show that protein-
uria is an independent risk factor predictive of graft failure
for recipients of all ages.7 At the same time, continued renal
graft function decline is a strong predictor of mortality in
renal transplant patients.6
The prevalence of proteinuria one year after trans-
plantation ranges from 11% to 45%,8 or even higher in
patients treated with proliferation signal inhibitors (PSI).
Two mechanisms for the development of proteinuria after
transplantation are described: tubular origin, due to inad-
equate protein reabsorption in the proximal tubule cells
damaged by ischaemia/reperfusion phenomena, rejection or
tubular toxicity, or glomerular origin due to increased passage
of higher molecular weight proteins such as albumin through
the glomerular barrier due to de novo or transplant glomerular
disease, chronic rejection or drug toxicity.
Proteinuria in transplantation is usually indicative of some
type of graft disease and generally tends to occur in rela-
tion to chronic graft nephropathy (histological substrate with
interstitial ﬁbrosis and tubular atrophy), acute rejection, trans-
plant glomerular disease or recurrence of primary kidney
disease.8–10 It can be associated with immunological or non-
immunological factors11 and factors related to both the donor
and the recipient. Degree of HLA sensitisation, age, obesity,
hypertension and other cardiovascular risk factors can all
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contribute to the development of post-transplant proteinuria.
Immunosuppressive therapy has also been associated with
proteinuria,12 with reports that PSI in particular can induce
it or make it worse if it already exists.13,14
Nephrotic-range proteinuria is associated with a worse
renal graft outcome, as occurs in other diseases in the
native kidney. However, urinary protein excretion usually con-
sidered as mild (<500 mg/day) from the ﬁrst months after
transplantation15 is also associated with worse transplanta-
tion outcomes and leads to much poorer graft and patient
survival rates, and may even provide information on the
graft.16–17 However there are no studies that focus on the evo-
lution of urinary protein excretion and its repercussion on
renal graft survival.
Objectives
To analyse the prevalence of proteinuria in the renal trans-
plant population in a particular regional area (Andalusia in
southern Spain). To identify contributory factors and the con-
sequences of proteinuria, particularly for graft and patient
outcome. To evaluate the impact of the evolution of urinary
protein excretion over time on graft survival.
Patients  and  methods
We  present data from the Renal Transplant Registry of Andalu-
sia, which forms part of a general registry of replacement
treatment for chronic kidney disease in the region that has
been in operation since 1984.
For this review, we  have analysed the data from 1 January
2000 to 31 December 2009, continuing the observation up to
25 May 2012 (12.25 years or 147 months). Data were collected
retrospectively for the years 2000–2003 and prospectively from
2004 to 2009. We  performed the analysis on the urinary protein
excretion records available for 1815 patients after a median
follow-up of 77.89 ± 32.94 months (12–147) during this period.
The urinary protein excretion, or simply proteinuria, was
quantiﬁed as mg/day, categorising the patients for the analysis
into three levels according to severity:
I. Urinary protein excretion below 300 mg a day
II. Urinary protein excretion 300–1000 mg  a day
III. Urinary protein excretion over 1000 mg  a day
The urinary protein excretion data were collected at two
patient follow-up points, three months and one year after
transplantation, leading to the creation of 6 groups of patients
according to severity of urinary protein excretion and time of
determination: I3m, II3m and III3m, according to the classiﬁ-
cation at 3 months and I1y, II1y and III1y, for one year after
transplant.
Statistical analysis: The SPSS v21 statistical package was
used.
An overall descriptive analysis was performed on the
entire study population. Comparative analysis was carried
out according to proteinuria groups, for which we performed
a bivariate analysis using ANOVA, applying Welch’s test for
those groups in which there was a lack of homoscedasticity
in the variances of the groups. For analysis of multiple com-
parisons in quantitative variables that showed statistically
signiﬁcant differences with respect to the proteinuria groups,
we used multiple comparison tests indicated for groups with
unequal variances and Bonferroni for groups with equal
variances. Pearson’s Chi-square test was used to compare
qualitative variables.
The level of signiﬁcance was considered to be p < 0.05.
Patient and graft survival censored for death was studied
by a Kaplan–Meier analysis and a multivariate analysis was
performed using a Cox regression model by means of manual
stepwise regression.
The following variables were introduced into this model:
donor age; donor gender, cause of donor death; recipient
age; recipient gender; pre-transplant cytotoxic antibodies;
maximum cytotoxic antibodies; HLA-A, -B and -DR  incompat-
ibility; ACE inhibitors (3 months); ARA2 (3 months); creatinine
(3 months); creatinine (1 year); proteinuria (3 months); and
proteinuria (1 year).
Results
Epidemiological  data  and  overall  descriptive  analysis
Pre-transplant and post-transplant data are shown in Table 1.
Distribution  by  group  and  changes  in  proteinuria  in  the
ﬁrst  year
The analysis was performed with the three-month urinary
protein excretion determination in 1815 patients.
The distribution of cases by degree of urinary protein
excretion at three months and one year and the mean deter-
minations are shown in Table 2. The three levels had similar
proportions.
At one year, in the majority of patients, urinary protein
excretion remained in the same range as at three months
or had decreased. The urinary protein excretion range had
increased (progression) in only 208 patients (12%) at one year,
1233 (70.5%) remained stable with the same degree (stable)
and in 306 (17.5%), the range had improved (improvement)
(Table 3).
Bivariate  analysis
Comparing the resulting groups, we found:
(a) Pre-transplant variables. Shown in Table 4.
There were signiﬁcant differences between proteinuria
groups in donor age, cause of donor death, recipient gender,
maximum cytotoxic antibody values (% PRA) and induction
therapy received.
With regard to the cause of donor death, we found that
organs from older donors and donors who died as a result of
a CVA (ischaemic or haemorrhagic) had more  urinary protein
excretion than those from donors who died from any other
cause.
Regarding immunosuppressive induction therapy received,
we found no difference in urinary protein excretion at three
months between patients who received no induction therapy
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Table 1 – Pre-transplant variables considered overall (the ﬁrst column) and overall post-transplant data in all patients
studied (the second column).
Overall pre-transplant data Overall post-transplant data
Donor age (years) 47.4 ± 16.2 (5–79) Patient living at end
of follow-up (%)
88.5
Donor gender (male) (%) 61.7 Functioning graft at end
of follow-up (%)
87.9
Donor death (CVA) (%) 60.9 Delayed renal function (%) 37.4
Recipient age (years) 47.2 ± 14.0 (1–79) Creatinine mg/dl (3 months) 1.59 ± 0.70
Recipient gender (male) (%) 61.1 Creatinine mg/dl (1 year) 1.50 ± 0.65
Cytotoxic antibodies (%PRA) 3.1 ± 11.6 (87.3% PRA < 25) Urinary protein excretion
3 monthsb,c (mg/24 h)
332.5  (75/200/362)
Maximum cytotoxic antibodies (%PRA) 11.5 ± 23.5(76.2% PRA < 25) Urinary protein excretion
1 yearb,c(mg/24 h)
308.4 (40/172/324)
Incompatibilities hla A/B/DR 0.9 ± 0.8/1.1 ± 0.8/0.7 ± 0.7 Hypertension 3 months (%) 73.9
1st grafta (%) 86 Number of anti-hypertensive
drugs (3 months)
1.7  ± 0.8 (1–5)
ESRD caused by diabetes (%) 11 ACE inhib./AIIRA 3 months (%) 4/31.5
Total cholesterol (mg/dl) 158.4 ± 44.1 (41–385) CyA/TAC (%) 10.2/8 3.5
Triglycerides (mg/dl) 144.5 ± 89.4 (31–688) PSI/Azathioprine/Mycophenolate
(%)
7.9/0.3/91.5
Lipid-lowering drugs (%) 18.4 Induction with antibodiesd (%) 43.3
a 1st and 2nd transplants 12.5%; 3rd transplant 1.5% of the patients.
b Expressed as mean and percentiles (25, 50, 75).
c Urinary protein excretion according to donor age at three months (Q1: 379 mg/24 h; Q2: 250 mg/24 h; Q3: 324 mg/24 h; Q4: 431 mg/24 h) p = 0.006,
and at one year (Q1: 266 mg/24 h; Q2: 265 mg/24 h; Q3: 283 mg/24 h; Q4: 367 mg/24 h) p = 0.001.
d 83.7% with anti-CD25 and 16.3% with antithymocyte globulins (ATG).
(urinary protein excretion 314 mg/24 h), those who received
antithymocyte globulin (ATG) (387 mg/24 h) and those who
received anti-CD25 antibodies (basiliximab or daclizumab)
(350 mg/24 h).
However, one year after transplant, patients who had
received thymoglobulin induction had higher levels of uri-
nary protein excretion than those who  had received anti-CD25
and those with no induction: 650 mg/24 h vs 280 mg/dl and
325 mg/24 h, respectively.
(b) Post-transplant variables: See Table 5.
We  found that most patients with more  urinary protein
excretion had more  delayed renal function, more  hyperten-
sion at three months and required a greater number of
antihypertensives to control it. The groups with more  pro-
teinuria also had worse renal function. At the end of the
observation period, there were a lower proportion of function-
ing grafts in groups with higher proteinuria. In addition, with
the urinary protein excretion measured at one year, we  found
a higher proportion of deaths among patients with proteinuria
above 1 g/24 h.
Table 2 – Urinary protein excretion at three months and one year in each of the classiﬁed groups.
Groups according to
urinary protein
excretion severity
Patients (N, %) Urinary protein
excretion (mg/24 h)
3 months
Patients (N, %) Urinary protein
excretion (mg/24 h)
1 year
Mean ± sd deviation Median Mean ± sd deviation Median
<300 1192 (65.7%) 123 ± 87 109 1250 (71.6%) 110 ± 92 100
300–1000 538 (29.6%) 481 ± 174 420 421 (24.1%) 488 ± 178 20
>1000 85 (4.7%) 2336 ± 2067 1554 76 (4.4%) 2559 ± 2049 1742
Table 3 – Changes in urinary protein excretion over time: number of patients in each group at 3 months and 1 year.
Urinary protein excretion at 1 year
<300 mg/24 h 300 mg-1 g/24 h >1 g/24 h Total patients
Urinary protein
excretion at 3
months
<300 mg/24 h 978 162 19 1159
300 mg−1 g/24 h 260 225 27 512
>1 g/24 h 12 34 30 76
Total patients 1250 421 76 1747
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Table 4 – Pre-transplant variables. Variables found to be statistically signiﬁcant are shown in bold.
Groups Urinary protein excretion 3 months Urinary protein excretion 1 year
Group I3m Group II3m Group III3m p Group I1y Group II1y Group III1y p
Donor age (years) 46.3 ± 16.1 49.7 ± 16.4a 50.2 ± 17.7a 0.02 46.9 ± 16.1 48.2 ± 16.8 48.0 ± 17.9 0.65
Donor gender (% M) 62.7 60.2 56.5 0.40 62.6 61.4 54.6 0.37
Donor death (%)
CVA/other
62.3/69.9a 32/27a 5.7/3.1a 0.002 66.8/72a 24.7/21.4 5.1/2.7a 0.02
Cold ischaemia
(min)
1021  ± 1824 1093 ± 2961 1012 ± 471 0.91 1009 ± 1868 1146 ± 3169 985 ± 490 0.75
Recipient age (years) 47.1 ± 13.9 47.8 ± 13.8 45.5 ± 15.8 0.34 47.1 ± 13.9 47.8 ± 13.8 45.5 ± 15.8 0.65
Recipient gender (%
M)
58.0c 67.8c 62.4 0.001 59.3c 66c 60 0.05
Pre-transplant
diabetes
10.9 11.8 8.3 0.61 9.9 13.1 12.2 0.17
Cholesterol
(pre-transplant)
159 ± 44 155  ± 44 157 ± 41 0.40 159 ± 44 157 ± 41 162 ± 52 0.81
Triglycer.
(Pre-transplant)
142 ± 85 146 ± 94 155 ± 99 0.54 142 ± 89 146 ± 82 184 ± 117 0.07
Pre-transpl.
lipid-low. drugs
18.2 18.4 20.2 0.89 18.4 17.6 23 0.55
Pre-transplant. Cyto.
Antib.
2.6  ± 10.2 3.6 ± 12.4 7.2 ± 19.9 0.05 2.9 ± 11.0 3.4 ± 11.7 3.3 ± 13.3 0.72
Max. Cyto. Antib. 9.9 ± 21.6b,c 13.7 ± 26.1c 19.0 ± 30.1b 0.001 10.9 ± 23.1 13.1 ± 24.6 9.1 ± 21.0 0.19
No. grafts (1/2/3) 65.5/30/4.5 65.8/28/6.2 66/6/29.6/3.8 0.80 85/13/2 87/11/2 82/18/0 0.38
HLA-A incomp. 0.9 ± 0.8 0.9 ± 0.8 1.0 ± 0.8 0.43 0.9 ± 0.8 1.0 ± 0.8 0.86 ± 0.8 0.38
HLA-B incomp. 1.1 ± 0.8 1.1 ± 0.8 1.1 ± 0.8 0.95 1.1 ± 0.8 1.2 ± 0.8 1.1 ± 0.9 0.72
HLA-DR incomp. 0.7 ± 0.7 0.7 ± 0.7 0.8 ± 0.7 0.47 0.7 ± 0.72 0.7 ± 0.74 0.8 ± 0.7 0.45
a Among the three groups.
b Between groups I3m and III3m.
c Between groups I3m and II3m  and between groups I1y and II1y.
Table 5 – Post-transplant variables according to urinary protein excretion group at three months and one year.
Comparison of qualitative variables using Pearson’s Chi-square test.
Groups Urinary protein excretion 3 months Urinary protein excretion 1 year
Group I3m (%) Group II3m (%) Group III3m (%) p Group I1y (%) Group II1y (%) Group III1y (%) p
Patients living 89.1 88.1 82.4 0.16 90.8b 86.94 78.95b 0.000
Functioning graft 91.4a,b 84.9a 58.8b 0.000 92.96b,c 82.90a,c 51.32a 0.000
Delayed renal
function
35.0a 41.3a 45.9 0.01 37.7 34.8 48.7 0.06
Hypertension 3
months
72.4  76.8 74.1 0.18 72c 77.6c 79.4 0.04
Anti-hypertensives
(3 months)
1.7  ± 0.8 1.8 ± 0.8 1.8 ± 0.8 0.36 1.7 ± 0.8a 1.9 ± 0.8a 1.8 ± 0.9 0.005
ACE inhib. 3 months 3.5 4.8 6.3 0.27 3.6 5.6 4.5 0.19
AIIRA 3 months 30.3 34.2 30.0 0.27 30.1 34.9 32.4 0.19
Creatinine (3
months)
1.5  ± 1.3a,c 1.8 ± 2.6a 2.1 ± 1.0c 0.000 1.5 ± 1.8a 1.8 ± 2.1a 1.8 ± 0.8 0.007
Creatinine (year) 1.4 ± 1.5a,c 1.6 ± 0.7a 2.0 ± 0.9c 0.0001 1.4 ± 1.4* 1.7 ± 0.7* 2.1 ± 1.3* 0.000
a Between groups I3m and II3m and between groups I1y and II1y.
b Between groups I3m and III3m and between groups I1y and III1y.
c Between groups II3m and III3m and between groups II1y and III1y.
d Among the three groups.
Table 6 – Renal function according to changes in the urinary protein excretion between three months and one year.
Proteinuria progression Creatinine 3
months (mg/dl)
Creatinine 1 year
(mg/dl)
Progressed (n = 208) 1.79 ± 2.76 1.72 ± 1.03 p < 0.05
Stable (n = 1233) 1.54 ± 0.89 1.49 ± 1.50 p < 0.001
Improved (n = 306) 1.89 ± 3.40 1.54 ± 0.59 p < 0.01
p = 0.007 p = 0.08
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(c) Lastly, we  studied changes in urinary protein excretion
between three months and one year. Based on this, we analysed
renal function, measured as serum creatinine, at three months
and one year after transplantation; Table 6 shows patients in
whom urinary protein excretion progressed, remained stable
or improved. We found differences in renal function at three
months according to whether the urinary protein excretion
later progressed, stabilised or improved (p = 0.007); however,
there was  no difference between groups one year after trans-
plant (p = 0.08).
Analysing changes in renal function measured as serum
creatinine, we  found that it improved signiﬁcantly between
three months and one year after transplantation in all groups,
but the degree of signiﬁcance was greater in patients in whom
the urinary protein excretion stabilised or improved and lower
in patients whose urinary protein excretion progressed.
Analysis  of  patient  survival
In our population considered as a whole, the patient survival
rate at 5 years was 93.1%, at 10 years 82% and at the end of the
study (12.25 years), 78%.
Patient survival according to urinary protein excretion:
(1) According to level of urinary protein excretion at 3 months, we
found no differences in survival among the 3 groups (log
rank, p = 0.389) (Fig. 1A).
(2) According to level of urinary protein excretion at 1 year, we
found signiﬁcant differences in survival rates between
groups (log rank, p = 0.001) (Fig. 1B).
(3) Analysing patient survival according to progression of uri-
nary protein excretion, i.e. whether urinary protein excretion
progressed between three months and one year compared
to those who remained stable or improved, we found sig-
niﬁcant differences.
(3.1) Overall patient survival is shown in Fig. 2A: for those
in whom urinary protein excretion progressed, the
difference in survival is signiﬁcant, becoming more
apparent from the 5th year on. There were no dif-
ferences in survival between the groups of patients
whose urinary protein excretion remained stable or
improved.
(3.2) We  then analysed each urinary protein excretion
group at three months and their progress at one year.
(3.2.1) Taking the urinary protein excretion
<300 mg/24 h group as reference and
analysing those whose urinary protein excre-
tion progressed and those who remained
within that range, we  found differences in
survival (p = 0.000) (Fig. 2B).
(3.2.2) Taking the urinary protein excretion
300 mg−1 g/24 h group and analysing out-
comes for those whose urinary protein
excretion worsened, remained stable or
improved, it can be seen from Fig. 2C that
there are differences in survival at 10 years
between the group that progressed and the
other two groups (p = 0.000). There were no
differences in survival between patients
whose urinary protein excretion remained
stable or improved.
(3.2.3) In the group with proteinuria more  of 1 g/24 h
at three months, 40% remained in the same
range at one year and 60% improved. In
these two cases patient survival remained
unchanged (p = 0.793) (Fig. 2D).
Analysis  of  graft  survival  censored  for  death
(1) Carrying out the analysis censoring the 209 deaths with
functioning graft, the graft survival rate at 5 years was
93.8%, at 10 years 84.3% and at the end of the study
(12.25 years), 83.3%.
(2) The K–M curves for graft survival censored for death for the
three groups according to level of urinary protein excretion
at 3 months and one year are shown in Fig. 1C and D (log
rank, p = 0.000), with differences among the three groups.
(3) Analysis of graft survival for all patients according to pro-
gression of urinary protein excretion:
(3.1) Analysing all patients with urinary protein excretion
who progressed, remained stable or improved from
three months to one year as a whole, we  found sig-
niﬁcant differences (Fig. 3A).
(3.2) We then analysed each urinary protein excretion
group at three months and their progress at one year.
(3.2.1) Taking the urinary protein excretion
<300 mg/24 h group as reference and
analysing those whose urinary protein excre-
tion progressed and those who  remained
within that range, we  found differences in
graft survival (Fig. 3B).
(3.2.2) Taking the proteinuria 300 mg−1 g/24 h group
and analysing outcomes for those whose uri-
nary protein excretion worsened, remained
stable or improved, there were differences in
survival (Fig. 3C).
(3.2.3) In the group with proteinuria more  of 1 g/24 h
at three months, 40% remained in the same
range at one year and 60% improved. There
were differences in survival (Fig. 3D).
Multivariate  analysis
Analysis  of  factors  inﬂuencing  patient  survival  time
Both the age of the recipient and the age of creatinine at one
year were found to be risk factors for the death of the patient
(Table 7).
The risk of death is 1059 times greater for every year of
the patient’s age at transplant and 1070 greater for every mil-
ligramme of creatinine at one year after transplantation.
Analysis  of  factors  inﬂuencing  graft  survival  time
Risk factors for graft loss were found to be: proteinuria and
serum creatinine. The resulting model formed by the variables
is shown in Table 8.
- Serum creatinine: The risk of graft loss was 1.053 and
1.077 times greater for every milligramme of creatinine at
three months and one year, respectively.
- Proteinuria: The risk of graft loss was 1.03 and 1.01 times
greater for every 100 milligrams of urinary protein excretion
at three months and one year, respectively.
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Fig. 1 – Patient survival and graft survival censored for death. Kaplan–Meier survival: Shows patient survival according to
urinary protein excretion group at three months (Panel A) and one year (Panel B) and graft survival censored for death
according to urinary protein excretion group at three months (Panel C) and one year (Panel D). There are no differences in
patient survival at three months with urinary protein excretion. With urinary protein excretion groups at one year, there are
signiﬁcant differences between groups I and II (p < 0.05) and between I and III (p < 0.001); continuous line – group I (urinary
protein excretion < 300 mg/day), short dashed line – group II (urinary protein excretion 300–1000 mg/day) and long dashed
line – group III (urinary protein excretion > 1000 mg/day). With proteinuria groups at both three months and one year, there
are signiﬁcant differences in graft survival among the three groups (p < 0.001); continuous line – group I (urinary protein
excretion < 300 mg/day), short dashed line – group II (urinary protein excretion 300–1000 mg/day) and long dashed line –
group III (urinary protein excretion > 1000 mg/day).
Discussion
We  studied a population of 1815 kidney transplants performed
since 2000 with a follow-up period of up to 12.25 years to
analyse the impact of proteinuria on renal transplantation
outcomes.
Analysing factors that can inﬂuence the development of
proteinuria, we  found donor-related factors, such as cause
of death (CVA vs non-CVA), to be determinants. In our case, the
groups with the highest levels of proteinuria were recipients
from donors who had died from cerebrovascular causes. It
might be assumed that grafts from donors who have died from
a CVA would have a worse cardiovascular proﬁle. Since we
believed that this relationship might be inﬂuenced by donor
age, we analysed the cause of death, whether CVA or not,
according to quartiles of donor age and found signiﬁcant dif-
ferences: as expected, there were more  deaths from CVA in
older age groups. We  also found differences in proteinuria
according to quartiles of donor age, especially at three months
Table 7 – Cox regression: patient survival.
Variables B Sig. Exp(B) 95.0% CI for Exp(B)
Lower Upper
Recipient age 0.057 0.000 1.059 1.046 1.072
Creatinine (year) 0.068 0.005 1.070 1.021 1.122
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Fig. 2 – Patient survival according to progression of urinary protein excretion. Panel A shows overall survival of all the
patients according to progression of urinary protein excretion from three months to one year post-transplant. Survival is
worse (p = 0.000) for those with progression (who change to a higher proteinuria level group) compared to those with no
change (stable) or who  improve (change to a lower urinary protein excretion level group). There were no differences in
survival between the groups of patients whose proteinuria remained stable or improved. Panel B shows patients with
urinary protein excretion of less than 300 mg/day at three months, who remained at that level (stable) at one year or
progressed (changed to a higher proteinuria level group), in which case, survival worsened. Panel C shows patients with
urinary protein excretion of 300–1000 mg/day at three months, and differences in survival according to whether their
urinary protein excretion range improved, remained stable or progressed at one year. Panel D shows the survival of the
group of patients with proteinuria above 1 g/day at three months according to whether their urinary protein excretion
remained within the same range (stable) or improved at one year.
after transplantation, where donor grafts of the extreme age
quartiles (1st and 4th) were those with most proteinuria.
This leads us to believe that the age of the donor also inﬂu-
ences the development of proteinuria, although we only found
differences in the analysis of donor age at three months and
not at one year by proteinuria groups. Recent studies18–21 show
that older donor age has a negative effect on renal graft, both in
deceased-donor and living-donor donation, but none of these
studies analyse proteinuria. Many authors have found a higher
degree of delayed renal function in older donors.22 In our case,
Table 8 – Cox regression: graft survival.
Variables B Sig. Exp(B)  95.0% CI for Exp(B)
Lower Upper
Proteinuria (year) 0.000 0.000 1.0001 1.00007 1.00014
Proteinuria (3 months) 0.000 0.000 1.0003 1.0002 1.0005
Creatinine (3 months) 0.052 0.006 1.053 1.015 1.093
Creatinine (year) 0.077 0.000 1.080 1.045 1.117
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Fig. 3 – Graft survival according to progression of urinary protein excretion: Panel A shows overall survival for all the
patients according to progression of proteinuria from three months to one year post-transplant (p = 0.000). There were  no
differences in survival between the groups of patients whose urinary protein excretion remained stable or improved. Those
who progressed had worse survival than those who  remained at the same level of proteinuria (stable) or improved. Panel B
shows patients with urinary protein excretion of less than 300 mg/day at three months who remained at that level (stable)
at one year or progressed (changed to a higher proteinuria level group), in which case survival worsened, compared to
94.4%, 86.4% and 85.3% for those whose urinary protein excretion remained at <300 mg/day at one year (p = 0.000). Panel C
shows patients with proteinuria of 300–1000 mg/day at three months, and differences in survival according to whether their
proteinuria range improved, remained stable or progressed at one year (p = 0.000). Panel D shows the survival of the group of
patients with proteinuria above 1 g/day at three months according to whether their proteinuria remained within the same
range (stable) or improved at one year (p = 0.000).
delayed renal function was associated with higher levels of
proteinuria and a greater risk of graft loss.
Moreover, in addition to our group, other authors23 have
found that higher pre-transplant levels of cytotoxic antibodies
negatively affect graft outcome; in our case, we found that
patients with higher antibody levels had more  proteinuria and,
indirectly, worse graft outcome.
Our patients who  had more  post-transplant hypertension
had more  proteinuria and worse graft outcome, with post-
transplant hypertension acting as an independent factor for
graft loss. This could be explained by the fact that hyperten-
sion is an expression of multiple factors, some graft-related,
some recipient-related and others related to immunosup-
pressive therapy or chronic renal disease,24 which continue
after the transplant as cardiovascular disease; in this clini-
cal setting, we know that the renin–angiotensin–aldosterone
axis (RAAS) is activated and also, that this activation favours
the onset of proteinuria.25 Improvement of proteinuria and
its consequences have also been reported after treatment
with RAAS blockers.26 In our case, the percentage of patients
treated with angiotensin converting enzyme (ACE) inhibitors
and angiotensin II receptor antagonists (AIIRAs) at three
months after transplantation was small and no differences
were, therefore, found between proteinuria groups.
Immunosuppressive induction therapy affects the renal
graft.27 We analysed induction therapy and, although we  did
not ﬁnd it to be a risk factor for graft loss, we did ﬁnd
that patients who had received thymoglobulin had signiﬁ-
cantly more  proteinuria one year after transplantation than
those treated with anti-CD25 or those who had received no
induction. Although this ﬁnding may seem paradoxical, one
explanation could be that in our region, use of thymoglobulin
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induction is rare and conﬁned to patients with high levels of
anti-HLA sensitisation pre-transplant.
We found that post-transplantation proteinuria (at three
months and one year) is predictive of graft outcome and is
associated with poorer renal function, a lower graft survival
rate and even with higher patient mortality rates. In the lit-
erature, there is evidence that even for the same degree of
renal dysfunction, increased proteinuria can increase the risk
of cardiovascular death.28 Oblak et al. recently reported that
patients who  have had an episode of acute rejection followed
by increased proteinuria have worse outcomes than those
who  have suffered rejection but no increase in proteinuria,29
with both worse graft survival and increased risk of death.
Some authors, such as Roodnat,30 believe that proteinuria
affects not only graft survival, as we  found, but also that of
the patient. In our multivariate analysis, we  failed to demon-
strate that severity of proteinuria was associated with worse
recipient survival. In the Kaplan–Meier study, higher levels
of proteinuria at one year correlated with worse patient sur-
vival, but this may only reﬂect their association with worse
renal function, which, as in the majority of published stud-
ies, was identiﬁed as a predictor of mortality in the adjusted
analysis.
However, we  did ﬁnd that the changes in proteinuria
over time seemed to signiﬁcantly affect transplant outcome,
worsening patient and graft survival in those in whom
proteinuria worsened between three months and one year
post-transplantation. Proteinuria remained stable in more
than two thirds of our patients between three months and
one year post-transplantation, while it worsened in 12% and
improved in 18%.
Compared to cases in which proteinuria improved or
remained stable between three months and one year, recipient
survival was signiﬁcantly worse in the group of patients with
worsening proteinuria, regardless of the level they started
with (<300 mg  or 300–1000 mg/day). Nevertheless, improve-
ment in their proteinuria had no effect on patients survival.
We think that in these patients with improvement in
proteinuria (18%), this could be related to the problems
after transplant and disappears in the ﬁrst months, but not
with graft pathology. This group, which improves proteinuria
has not improved survival, possibly because the proteinuria
was not a problem relative to the graft.
When analysing graft survival overall for all patients, we
found that the factor most likely to worsen survival is pro-
gression of proteinuria. However, when survival for each
proteinuria group at three months and one year were analysed
separately, here we  did ﬁnd that progression of proteinuria
was associated with worse survival rates, while improving
proteinuria also improved graft survival, in both cases com-
pared to patients who remained stable. It might be expected
that the difference in survival would be related to a paral-
lel worsening in renal function, but we found no differences
in serum creatinine at one year in terms of whether the
proteinuria progressed, remained stable or improved. We
found that there were differences at three months, with renal
function being worse in the group in which proteinuria sub-
sequently improved. This may be the result of immediate
post-transplant factors that could be resolved, allowing both
proteinuria and renal function to improve.
We are therefore able to state that the progression of pro-
teinuria in the ﬁrst year after transplantation, on its own, will
predict long-term graft survival. The mechanism underlying
this association is beyond the scope of this work. Protein-
uria, especially its progression, may indicate one or more
ongoing damaging processes, such as chronic rejection, recur-
rence of underlying disease or overload of a kidney which
was inadequate due to donor characteristics. Moreover, high-
level proteinuria may itself exacerbate the progress of the
organ.
Based on these results, we believe that in addition to
analysing the degree of proteinuria at a particular time, we
should monitor changes over time.
In another vein, our analysis found that factors that appear
to increase the risk of proteinuria at three months, such as
donor age, disappear at one year, while the cause of death
of the donor remains among the factors that inﬂuence the
development of proteinuria both at three months and one
year.
In our case, as had previously been found by authors of our
group,31 the Cox regression showed the age of the recipient
as mortality factors. In addition, renal function, as measured
by serum creatinine, at one year post-transplant was also a
determinant of patient survival.
In the Cox analysis for graft survival, proteinuria, renal
function at three months and one year post-transplant were
predictive factors for graft loss.
In conclusion, we  found that proteinuria is a marker of poor
renal graft outcome, especially when it progresses. Although
its cause may be multifactorial, it is clear that we  can consider
it as an epiphenomenon of a series of events that will ulti-
mately lead to a worse outcome for the transplanted patient.
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